Description
Ryuvidine is a potent inhibitor of SET domain-containing protein 8 (SETD8) (IC₅₀ = 0.5 µM) that suppresses monomethylation of H4K20 in vitro. It displays weak inhibiton against cyclin-dependent kinase 4 (Cdk4; IC₅₀ = 6 µM for Cdk4/cyclin D1). Induces S phase accumulation in HEK293T cells. Cytotoxic against a range of human cancer cells.
Ryuvidine is a potent inhibitor of SET domain-containing protein 8 (SETD8) (IC₅₀ = 0.5 µM) that suppresses monomethylation of H4K20 in vitro. It displays weak inhibiton against cyclin-dependent kinase 4 (Cdk4; IC₅₀ = 6 µM for Cdk4/cyclin D1). Induces S phase accumulation in HEK293T cells. Cytotoxic against a range of human cancer cells.
Alternate Name/Synonyms: 2-Methyl-5-[(4-methylphenyl)amino]-4,7-benzothiazoledione
Appearance: Dark purple solid
Formulation: N/A
CAS Number: 265312-55-8
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₁₅H₁₂N₂O₂S
Molecular Weight: 284.33
Cell-Permeable?: Yes
Purity: ≥98%
Solubilities: DMSO (~5 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent inhibitor of SET domain-containing protein 8 (SETD8)
MDL Number: N/A
PubChem CID: 481747
SMILES: CC1=CC=C(C=C1)NC2=CC(=O)C3=C(C2=O)N=C(S3)C
InChi: InChI=1S/C15H12N2O2S/c1-8-3-5-10(6-4-8)17-11-7-12(18)15-13(14(11)19)16-9(2)20-15/h3-7,17H,1-2H3
InChi Key: HFPLHASLIOXVGS-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |